Replies to post #197270 on Biotech Values

[DewDiligence]

OCRX is +41%(!) in AH trading. Nevertheless, something in the controlled release of oral OCR-002 is apparently not quite right or they wouldn't have to "optimize" it, so I concur with your commentary.

[DewDiligence]

OCRX +21% on last night’s PR about PK data of oral OCR-002 (#msg-118538497). Such a large percentage gain is probably unwarranted based on the PK information per se (as noted in #msg-118538988, #msg-118538903), but this kind of jump is not uncommon when a biotech with a legitimate pipeline has been trading at an enterprise value close to zero.

[DewDiligence]

OCRX—Do you have anything to add to what you posted on this subject in November? T.i.a.